IP Library › Granted Patent US 12,661,362
Granted Patent B2
US 12,661,362 · App. 18/081,951 · Granted Jun 23, 2026

Methods for the prevention and treatment of hearing loss

Inventors: Jian Zuo (Carlsbad, CA); Pezhman Salehi Dermanaki (Elkhorn, NE); Marisa Laura Zallocchi (Omaha, NE); Sarath Vijayakumar (Omaha, NE)
Assignee: Ting Therapeutics, Inc.
A61K31/5377A61F11/00A61K31/122A61K31/165A61K31/167A61K31/397A61K31/506A61K31/513A61K31/517A61K31/609A61K31/7036A61K33/243A61K45/06A61P27/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,661,362
App. No.
18/081,951
Granted
Jun 23, 2026
Kind
B2
Abstract

Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise-induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims (1)

1 . A method to prevent ear hair cell loss caused by a chemotherapeutic agent comprising: administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is Niclosamide, or a pharmaceutically acceptable salt thereof to prevent ear hair cell loss caused by the administration of the chemotherapeutic agent, wherein the chemotherapeutic agent is Cisplatin.

Assignments (6)
MERGER AND CHANGE OF NAME Recorded Oct 10, 2024
From: TING THERAPEUTICS LLC; TING THERAPEUTICS, INC.
To: TING THERAPEUTICS, INC
Reel/Frame 069142/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2023
From: CREIGHTON UNIVERSITY
To: TING THERAPEUTICS LLC
Reel/Frame 063924/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023
From: DERMANAKI, PEZHMAN SALEHI
To: TING THERAPEUTICS LLC
Reel/Frame 063607/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023
From: ZUO, JIAN
To: TING THERAPEUTICS LLC
Reel/Frame 063607/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: VIJAYAKUMAR, SARATH
To: TING THERAPEUTICS LLC
Reel/Frame 062429/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2022
From: ZALLOCHI, MARISA LAURA
To: TING THERAPEUTICS LLC
Reel/Frame 062222/0327 →
Continuity (3)
Continuation PCTUS2021041199 · Jul 10, 2021
Provisional Application 63050568 · Jul 10, 2020
Related Publication 20230285418A1 · Sep 14, 2023
References Cited (25)
US 8420595B2 · Kopke et al. · 2013 [cited by applicant]
US 9572815B2 · Zuo et al. · 2017 [cited by applicant]
US 20040110719A1 · Campbell · 2004 [cited by applicant]
US 20080280955A1 · McCamish · 2008 [cited by applicant]
US 20130085112A1 · Collard et al. · 2013 [cited by applicant]
US 20140235631A1 · Bunt et al. · 2014 [cited by applicant]
US 20160089371A1 · Liu et al. · 2016 [cited by applicant]
US 20170327557A1 · Chen · 2017 [cited by applicant]
US 20180161340A1 · Zuo et al. · 2018 [cited by applicant]
US 20200093923A1 · Zuo et al. · 2020 [cited by applicant]
WO 2016114655A1 · 2016 [cited by applicant]
WO 2018204764A1 · 2018 [cited by applicant]
Atkinson et al. “hair Cell Regeneration after ATOH1 Gene Therapy in the Cochlea of Profoundly Deaf Adult Guinea Pigs,” PLoS ONE, Jul. 18, 2014 (Jul. 18, 2014), vol. 9, Iss. 7, pp. 1-11. entire document. [cited by applicant]
Boanza et al. “A primary role fo the epidermal growth factor receptor in ommatidial spacing in the [cited by applicant]
Dabestani et al, Drug Repurposing of an EGF Inhibitor for Protection Against Noise-Induced Hearing Loss. 2020. Creighton University, M.Sc. Thesis. ProQuest, PQ No. 28001904; http://hld.handle.net/10504/127028. [cited by applicant]
Jarman et al. “The role of Atonal transcription factors in the development of mechanosensitive cells,” Seminars in Cell and Developmental Biology, May 1, 2013 (May 1, 2013), vol. 24, Iss. 5, pp. 438-447. entire document. [cited by applicant]
McDowell, Brian. International Preliminary Report on Patentability. PCT. Jun. 17, 2022. 1-15. [cited by applicant]
McDowell, Brian. International Search Report of the ISA. PCT. Nov. 15, 2021. 1-2. [cited by applicant]
Rodriquez, Kari. Written Opinion of the ISA. PCT. Nov. 15, 2021. 1-4. [cited by applicant]
Teitz et al., “CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss,” J. Exp. Med. Apr. 2, 2018, vol. 215, No. 4, pp. 1187-1203. [cited by applicant]
Lee et al “Ezetimibe, an NPC1L1inhibitor, is a potent Nrf2 activator that protectsmice from diet-induced nonalcoholic steatohepatitis” Free Rad/ Bio. and Med. V. 99 520-532 (2016). [cited by applicant]
Zhang et al. “NRF2 activation protects Auditory Hair cells from Cisplatin-Induced Ototoxicity Independent on Mitochondrial ROS production” Toxi. Lett. V. 331 (2020). [cited by applicant]
Li, R. et al. “Niclosamide Overcomes Acquired Resistance to Erlotinib Through Suppression of STAT3 in Non-Small Cell Lung Cancer” Mol. Can. Ther. V. 12 (10) pp. 2200-2212 ( 2013). [cited by applicant]
Salehi, p et al. “In Silico Transcriptomics Identifies FDA-Approved Drugs and Biological Pathways for Protection Against Cisplatin-Induced Hearing Loss” BioRxiv pp. 1-66 ( Jan. 18, 2022). [cited by applicant]
Vijayakumar, S. et al. “In Silico Transcriptome Screens Identify Epidermal Growth Factor Receptor Inhibitors as Therapeutics For Noise-Induced Hearing Loss” Sci. Adv. V. 10. pp. 1-19 ( 2024). [cited by applicant]